Pinatuzumab vedotin
Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities.
For research use only. We do not sell to patients.
- CAS No.: 1313706-14-7
-
Storage:
-80°C, protect from light
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1313706-14-7
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Pinatuzumab vedotin]
-
Synonyms
anti-CD22-vc-MMAE; DCDT2980S
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ranjana H Advani, et al. Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Trial Clin Cancer Res. 2017 Mar 1;23(5):1167-1176. [Content Brief]
[2]. Yip, V., et al., (2024). Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species. Xenobiotica; the fate of foreign compounds in biological systems, 54(8), 511–520. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)